Design, synthesis, and structure–activity relationships of diindolylmethane derivatives as cannabinoid CB2 receptor agonists
Sign Up to like & getrecommendations! Published in 2022 at "Archiv der Pharmazie"
DOI: 10.1002/ardp.202200493
Abstract: 3,3′‐Diindolylmethane (DIM), a natural product‐derived compound formed upon ingestion of cruciferous vegetables, was recently described to act as a partial agonist of the anti‐inflammatory cannabinoid (CB) receptor subtype CB2. In the present study, we synthesized… read more here.
Keywords: receptor agonists; design synthesis; cb2 receptor; efficacy ... See more keywords
Synthetic cannabinoid receptor agonists and their human metabolites in sewage water: Stability assessment and identification of transformation products.
Sign Up to like & getrecommendations! Published in 2021 at "Drug testing and analysis"
DOI: 10.1002/dta.3129
Abstract: Since their first appearance in 2008, synthetic cannabinoid receptor agonists (SCRAs) remain the most popular new psychoactive substances (NPS) in the EU. Following consumption, these drugs and their metabolites are urinary excreted and enter the… read more here.
Keywords: sewage water; synthetic cannabinoid; receptor agonists; cannabinoid receptor ... See more keywords
Effect of the α2‐receptor agonists medetomidine, detomidine, xylazine, and romifidine on the ketamine metabolism in equines assessed with enantioselective capillary electrophoresis
Sign Up to like & getrecommendations! Published in 2017 at "ELECTROPHORESIS"
DOI: 10.1002/elps.201700017
Abstract: The combination of ketamine and an α2‐receptor agonist is often used in veterinary medicine. Four different α2‐receptor agonists, medetomidine, detomidine, xylazine, and romifidine, which differ in their chemical structure and thus in selectivity for the… read more here.
Keywords: receptor; xylazine romifidine; receptor agonists; agonists medetomidine ... See more keywords
GLP-1 Receptor Agonists and SGLT2 Inhibitors for the Treatment of Type 2 Diabetes: New Insights and Opportunities for Cardiovascular Protection.
Sign Up to like & getrecommendations! Published in 2020 at "Advances in experimental medicine and biology"
DOI: 10.1007/5584_2020_494
Abstract: The risk of cardiovascular disease (CVD) (myocardial infarction, stroke, peripheral vascular disease) is twice in type 2 diabetes (T2D) patients compared to non-diabetic subjects. Furthermore, cardiovascular disease (CV) is the leading cause of death in… read more here.
Keywords: type diabetes; treatment; receptor agonists; cardiovascular protection ... See more keywords
Use of incretin-based drugs and risk of cholangiocarcinoma: Scandinavian cohort study
Sign Up to like & getrecommendations! Published in 2021 at "Diabetologia"
DOI: 10.1007/s00125-021-05508-1
Abstract: Concerns have been raised regarding a potential association of use of the incretin-based drugs dipeptidyl peptidase 4 (DPP4) inhibitors and glucagon-like peptide-1 (GLP-1)-receptor agonists with risk of cholangiocarcinoma. We examined this association in nationwide data… read more here.
Keywords: dpp4 inhibitors; receptor agonists; cholangiocarcinoma; glp receptor ... See more keywords
Cardiovascular Effects of Different GLP-1 Receptor Agonists in Patients with Type 2 Diabetes
Sign Up to like & getrecommendations! Published in 2018 at "Current Diabetes Reports"
DOI: 10.1007/s11892-018-1043-z
Abstract: Purpose of ReviewGlucagon-like peptide-1 receptor agonists (GLP-1 RAs) have positive effects on weight loss, blood pressure, hyperlipidemia, and glycemic control. They exhibit a broad range of effects on the cardiovascular system that are independent of… read more here.
Keywords: patients type; risk; glp ras; receptor agonists ... See more keywords
Glucocorticoids promote response to thrombopoietin-receptor agonists in refractory ITP: a case series
Sign Up to like & getrecommendations! Published in 2019 at "International Journal of Hematology"
DOI: 10.1007/s12185-019-02638-6
Abstract: A proportion of patients with immune thrombocytopenic purpura are refractory to multiple therapies including thrombopoietin-receptor agonists (TPO-RA). We report 10 patients who did not respond to a TPO-RA until the addition of a glucocorticoid. These… read more here.
Keywords: glucocorticoids promote; receptor agonists; promote response; thrombopoietin receptor ... See more keywords
Targeted 5-HT1F Therapies for Migraine
Sign Up to like & getrecommendations! Published in 2018 at "Neurotherapeutics"
DOI: 10.1007/s13311-018-0615-6
Abstract: Migraine is a common neurological disease characterised by the presence of attacks of unilateral, severe head pain accompanied by other symptoms. Although it has been classified as the sixth most disabling disorder, the available therapeutic… read more here.
Keywords: ht1f receptor; therapies migraine; receptor agonists; targeted ht1f ... See more keywords
Insights into a possible role of glucagon-like peptide-1 receptor agonists in the treatment of depression
Sign Up to like & getrecommendations! Published in 2021 at "Pharmacological Reports"
DOI: 10.1007/s43440-021-00274-8
Abstract: Graphic abstract Depression is a highly prevalent mood disorder and one of the major health concerns in modern society. Moreover, it is characterized by a high prevalence of coexistence with many other diseases including metabolic… read more here.
Keywords: depression; glucagon like; treatment; receptor agonists ... See more keywords
The effects of local microinjection of selective dopamine D1 and D2 receptor agonists and antagonists into the dorsal raphe nucleus on sleep and wakefulness in the rat
Sign Up to like & getrecommendations! Published in 2018 at "Behavioural Brain Research"
DOI: 10.1016/j.bbr.2017.11.006
Abstract: HIGHLIGHTSMicroinjection of SKF38393, bromocriptine and quinpirole into the DRN reduced REMS.Bromocriptine and quinpirole increased, in addition, wakefulness.The DAergic system plays a role in the regulation of the 5‐HT system. ABSTRACT The effects of the dopamine… read more here.
Keywords: raphe nucleus; dorsal raphe; receptor agonists; dopamine receptor ... See more keywords
P 71 Levodopa modulates beta and gamma oscillations in the cortico-basal ganglia loop with a higher efficacy than the dopamine receptor agonist apomorphine in experimental Parkinsonism
Sign Up to like & getrecommendations! Published in 2017 at "Clinical Neurophysiology"
DOI: 10.1016/j.clinph.2017.06.147
Abstract: The pharmacotherapy of Parkinson’s disease (PD) is based on levodopa, and dopamine receptor agonists, such as apomorphine. Although both types of agents provide beneficial clinical effects on motor and non-motor symptoms in PD clinical efficiency… read more here.
Keywords: beta gamma; cortico basal; receptor agonists; dopamine receptor ... See more keywords